|1.||Acín, Maria T: 1 article (11/2010)|
|2.||Higueras, F J: 1 article (11/2010)|
|3.||Vaquero, Maria P: 1 article (11/2010)|
|4.||Sánchez-Muniz, F J: 1 article (11/2010)|
|5.||Villalobos, Maria E: 1 article (11/2010)|
|6.||Bastida, S: 1 article (11/2010)|
05/01/1981 - "No appreciable formation of TxA3 and PGI3 is observed, although arterial thrombosis is depressed and bleeding time is prolonged. "
01/01/1979 - "The prostacyclin:thromboxane A2 ratio is important in the control of thrombus formation; manipulation of this ratio by small doses of aspirin (which will inhibit mainly platelet cyclooxygenase), a selective inhibitor of thromboxane formation, or the dietary use of a fatty acid like eicosapentaenoic acid (which would be the precursor for a delta17-prostacyclin (PGI3) but is transformed by the platelets into nonaggregating thromboxane A3) might have beneficial effects as antithrombotic therapies. "
11/01/2010 - "In addition, as a precursor of EPA and this last fatty acid of thromboxane A3, prostacyclin I3, serie-3 prostaglandines and serie 5-leukotrines and inhibitor/modulator of thromboxane A2, prostacyclin I2, serie-2 prostaglandines and serie 4-leukotrienes formation, the α-linolenic acid may reduce inflammation and thrombogenesis. "
|1.||Thromboxane A2 (A2, Thromboxane)
|4.||alpha-Linolenic Acid (Linolenic Acid)
|6.||Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)
|7.||Aspirin (Acetylsalicylic Acid)